ZA200603502B - Process for the preparation of polymorphs of selective serotonin reuptake inhibitor - Google Patents
Process for the preparation of polymorphs of selective serotonin reuptake inhibitor Download PDFInfo
- Publication number
- ZA200603502B ZA200603502B ZA200603502A ZA200603502A ZA200603502B ZA 200603502 B ZA200603502 B ZA 200603502B ZA 200603502 A ZA200603502 A ZA 200603502A ZA 200603502 A ZA200603502 A ZA 200603502A ZA 200603502 B ZA200603502 B ZA 200603502B
- Authority
- ZA
- South Africa
- Prior art keywords
- sertraline
- process according
- sertraline hydrochloride
- mixture
- cooling
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 title 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 title 1
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 claims abstract description 83
- 229960002073 sertraline Drugs 0.000 claims abstract description 60
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims abstract description 60
- 229960003660 sertraline hydrochloride Drugs 0.000 claims abstract description 45
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 66
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 38
- 239000002904 solvent Substances 0.000 claims description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 238000001816 cooling Methods 0.000 claims description 17
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 17
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000011541 reaction mixture Substances 0.000 claims description 14
- 239000007789 gas Substances 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 6
- -1 et hanol Chemical compound 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- ANFZRGMDGDYNGA-UHFFFAOYSA-N ethyl acetate;propan-2-ol Chemical compound CC(C)O.CCOC(C)=O ANFZRGMDGDYNGA-UHFFFAOYSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 17
- 239000002585 base Substances 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 11
- 239000008107 starch Substances 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 10
- 239000008108 microcrystalline cellulose Substances 0.000 description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 229920003109 sodium starch glycolate Polymers 0.000 description 6
- 229940079832 sodium starch glycolate Drugs 0.000 description 6
- 239000008109 sodium starch glycolate Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229940071117 starch glycolate Drugs 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
- C07C209/84—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1158MU2003 | 2003-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200603502B true ZA200603502B (en) | 2008-02-27 |
Family
ID=34586963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200603502A ZA200603502B (en) | 2003-11-04 | 2004-11-04 | Process for the preparation of polymorphs of selective serotonin reuptake inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7893300B2 (ja) |
| EP (1) | EP1682483B1 (ja) |
| JP (1) | JP4791970B2 (ja) |
| KR (1) | KR101161813B1 (ja) |
| CN (1) | CN1902157A (ja) |
| AT (1) | ATE469119T1 (ja) |
| AU (1) | AU2004289512A1 (ja) |
| CA (1) | CA2544684A1 (ja) |
| DE (1) | DE602004027401D1 (ja) |
| NZ (1) | NZ546902A (ja) |
| RU (1) | RU2376279C2 (ja) |
| WO (1) | WO2005047229A2 (ja) |
| ZA (1) | ZA200603502B (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2984109B1 (en) * | 2013-06-04 | 2019-09-25 | Dow Global Technologies LLC | Process for manufacturing lithium carboxymethyl cellulose |
| CN112552188B (zh) * | 2020-12-17 | 2023-07-28 | 山西仟源医药集团股份有限公司 | 盐酸舍曲林晶型i的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| US5734083A (en) * | 1996-05-17 | 1998-03-31 | Torcan Chemical Ltd. | Sertraline polymorph |
| IL152330A0 (en) * | 1997-07-01 | 2003-05-29 | Pfizer | Sertraline salts and sustained-release dosage forms of sertraline |
| US6500987B1 (en) * | 1998-11-27 | 2002-12-31 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
| US6495721B1 (en) * | 1999-08-09 | 2002-12-17 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride Form II and methods for the preparation thereof |
| TWI260315B (en) | 1999-10-29 | 2006-08-21 | Ciba Sc Holding Ag | Polymorphic forms of sertraline hydrochloride |
| AU780771B2 (en) * | 1999-12-21 | 2005-04-14 | Teva Pharmaceutical Industries Ltd. | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
| AU2003251290A1 (en) * | 2002-04-29 | 2003-11-17 | Teva Pharmaceutical Industries Ltd. | Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof |
-
2004
- 2004-11-04 RU RU2006119477/04A patent/RU2376279C2/ru not_active IP Right Cessation
- 2004-11-04 EP EP04798397A patent/EP1682483B1/en not_active Not-in-force
- 2004-11-04 CN CNA2004800397985A patent/CN1902157A/zh active Pending
- 2004-11-04 JP JP2006537441A patent/JP4791970B2/ja not_active Expired - Fee Related
- 2004-11-04 WO PCT/GB2004/004672 patent/WO2005047229A2/en active Application Filing
- 2004-11-04 DE DE602004027401T patent/DE602004027401D1/de active Active
- 2004-11-04 KR KR1020067010735A patent/KR101161813B1/ko not_active IP Right Cessation
- 2004-11-04 ZA ZA200603502A patent/ZA200603502B/en unknown
- 2004-11-04 AU AU2004289512A patent/AU2004289512A1/en not_active Abandoned
- 2004-11-04 CA CA002544684A patent/CA2544684A1/en not_active Abandoned
- 2004-11-04 NZ NZ546902A patent/NZ546902A/en not_active IP Right Cessation
- 2004-11-04 AT AT04798397T patent/ATE469119T1/de not_active IP Right Cessation
- 2004-11-04 US US10/577,714 patent/US7893300B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR101161813B1 (ko) | 2012-07-05 |
| RU2006119477A (ru) | 2007-12-20 |
| ATE469119T1 (de) | 2010-06-15 |
| US20070135524A1 (en) | 2007-06-14 |
| NZ546902A (en) | 2010-02-26 |
| US7893300B2 (en) | 2011-02-22 |
| KR20060123234A (ko) | 2006-12-01 |
| AU2004289512A2 (en) | 2005-05-26 |
| WO2005047229A2 (en) | 2005-05-26 |
| EP1682483B1 (en) | 2010-05-26 |
| EP1682483A2 (en) | 2006-07-26 |
| CA2544684A1 (en) | 2005-05-26 |
| WO2005047229A3 (en) | 2005-07-07 |
| DE602004027401D1 (de) | 2010-07-08 |
| AU2004289512A1 (en) | 2005-05-26 |
| JP2007510640A (ja) | 2007-04-26 |
| RU2376279C2 (ru) | 2009-12-20 |
| JP4791970B2 (ja) | 2011-10-12 |
| CN1902157A (zh) | 2007-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7319171B2 (en) | Sertraline hydrochloride form II and methods for the preparation thereof | |
| US20080085903A1 (en) | Novel crystalline forms of aripiprazole | |
| EP1224160B1 (en) | Process for the preparation of the polymorphic form II of sertraline hydrochloride | |
| JP2003518056A (ja) | 新規塩酸セルトラリン多形体、それらを調製するための方法、それらを含有する組成物およびそれらを用いる方法 | |
| EP2370433B1 (en) | A method for the preparation of tizanidine hydrochloride | |
| US20030191347A1 (en) | Venlafaxine base | |
| WO2003093217A1 (en) | Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof | |
| EP0304941B1 (en) | Pharmaceutically useful polymorphic modification of buspirone | |
| US7183272B2 (en) | Crystal forms of oxcarbazepine and processes for their preparation | |
| CN107531744A (zh) | 一种奥贝胆酸的新结晶形式及其制备方法 | |
| ZA200603502B (en) | Process for the preparation of polymorphs of selective serotonin reuptake inhibitor | |
| US6133269A (en) | Polymorphic form of doxazosin mesylate (form II) | |
| US7173153B2 (en) | Sertraline hydrochloride form II and methods for the preparation thereof | |
| CN102336701A (zh) | 硫酸卡维地洛的结晶、其制备方法及其在医药上的应用 | |
| US20040038985A1 (en) | Crystal forms of 1- [6-chloro-5-(trifluoromethly) -2-pyridinyl] piperazine hydrochloride | |
| CN114539135B (zh) | 一种左旋氨氯地平的新盐型及其制备方法和应用 |